Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Above 50 Day Moving Average – Time to Sell?

Minerva Neurosciences, Inc. (NASDAQ:NERV)’s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.21 and traded as high as $2.69. Minerva Neurosciences shares last traded at $2.68, with a volume of 242,714 shares traded.

Analysts Set New Price Targets

Several equities analysts have issued reports on NERV shares. HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, November 6th. StockNews.com initiated coverage on shares of Minerva Neurosciences in a report on Wednesday. They issued a “sell” rating on the stock.

Minerva Neurosciences Trading Up 13.1 %

The business has a 50-day moving average of $2.21 and a 200 day moving average of $2.54.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.